TOKYO, July 31 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 29 after discussing its R&D policy at a meeting of the board of directors held on the day and determined the R&D items as follows.
The company intends to actively strengthen R&D in the ophthalmologic & dermatological fields that are its priority and exclusive areas, and promote relevant affiliation, etc. with external entities.
1. Development code UF-021 (eye diseases)
The item in question is isopropyl unoproston, the effective ingredient of "Rescula(R) eyedrop 0.12%" that is marketed as a therapeutic drug for glaucoma and ocular hypertension. This drug is now being developed by R-Tech Ueno for the indication of retinitis pigmentosa. The drug is introduced to Sucampo Pharma Americas Ltd. in the USA to be developed for the indication of atrophic age-related macular degeneration.
2. Development code RTU-007 (eye diseases)
The license is obtained from Astellas Pharma Inc. for the substance to inhibit the enzyme that increases in patients with diabetes mellitus. We intend to proceed with the development of this substance to be indicated for diabetic cataract, diabetic retinopathy and age-related macular degeneration.
3. Development code RU-10 (eye diseases)
Dry eye is targeted for development of the drug that contains gene recombination human serum albumin as an effective ingredient. Though the clinical study is currently interrupted, we intend to look for overseas affiliation soon because the need for treatment of dry eye is globally unmet (that is, there are currently few therapeutic drugs).
4. Development code RK-023 (dermatological diseases)
This item is a physiologically active fatty acid derivative that is a new compound developed by R-Tech Ueno and is being developed as a drug indicated for male pattern alopecia. We intend to proceed with negotiations for affiliation in Japan and abroad in the future. We also plan to newly develop this drug indicated for eyelash hypotrichosis.
5. Development code RTU-1096 (dermatological and neurological diseases)
This compound newly developed by R-Tech Ueno demonstrates an unconventional action, VAP-1* inhibition. We intend to develop this compound as a drug indicated for atopic dermatitis, contact dermatitis and psoriasis vulgaris in the dermatological field, and diabetic neuropathy in the neurological field.
We plan to report on the development status of each item on the home page of R-Tech Ueno.
Vascular adhesion protein-1 (VAP-1) is also called semicarbazide-sensitive amine oxidase (SSAO). There are two types of VAP-1/SSAO, that is, the membrane-binding type present in the vascular endothelium and the free type present in the serum. The former serves as a molecule adherent to white blood cells and lymphocytes and is involved in inflammation while the latter detoxifies amine in the living body by its amine oxidase activity. In other words, VAP-1 is a protein that demonstrates two different functions. The increase in VAP-1/SSAO activity is observed in the serum and various tissues of patients with diabetes mellitus, atopic dermatitis, obesity, arteriosclerosis, heart disease, etc. In this regard, VAP-1 inhibitor inhibits the excessive function of VAP-1/SSAO.
About R-Tech Ueno, Ltd.
Representative Director & President: Yukihiko Mashima Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo Code No.4573, Osaka Securities Exchange; Hercules CONTACT: Koji Nakamura Business Management Department R-Tech Ueno, Ltd. Tel: +81-3-3596-8011 e-mail: email@example.com
|SOURCE R-Tech Ueno, Ltd.|
Copyright©2009 PR Newswire.
All rights reserved